# Pfizer Pipeline

As of August 9, 2013

# Disclaimer

- As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for candidates from Phase 3 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of August 9, 2013.

- Visit Pfizer.com/pipeline, Pfizer's online database where you can learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world.

# Table of Contents

# Pfizer Pipeline Snapshot




Pipeline represents progress of R&D programs as of August 9, 2013

Included are 55 NMEs, 17 additional indications, plus 4 biosimilars

4 projects discontinued since last update


Pipeline represents progress of R&D programs as of May 9, 2013

Included are 56 NMEs, 16 additional indications, plus 2 biosimilars

4 projects discontinued since last update

**Recent Approval**

- **Bosulif** for Treatment of Previously Treated Chronic Myelogenous Leukemia (EU)

# Pfizer Pipeline – August 9, 2013

| Therapeutic Area | Compound Name | Mechanism of Action (Phase 3 through regulatory approval) | Indication | Phase |
|---|---|---|---|---|
| Cardiovascular and Metabolic Diseases | ▶ Eliquis (apixaban) | Factor Xa Inhibitor | Venous Thromboembolism Prevention (U.S.) | Registration |
| | Eliquis (apixaban) | Factor Xa Inhibitor | Venous Thromboembolism Treatment | Phase 3 |
| | ertugliflozin (PF-04971729) | | Diabetes Mellitus-Type 2 | Phase 2 |
| | RN316 (PF-04950615) | | Hypercholesterolemia (Biologic) | Phase 2 |
| | PF-04937319 | | Diabetes Mellitus-Type 2 | Phase 2 |
| | PF-00489791 | | Diabetic Nephropathy | Phase 2 |
| | PF-04634817 | | Diabetic Nephropathy | Phase 2 |
| | PF-05231023 | | Diabetes Mellitus-Type 2 (Biologic) | Phase 1 |
| | PF-05175157 | | Diabetes Mellitus-Type 2 | Phase 1 |
| | RN317 (PF-05335810) | | Hypercholesterolemia (Biologic) | Phase 1 |
| | PF-06282999 | | Acute Coronary Syndrome | Phase 1 |
| | ▶ PF-06291874 | | Diabetes Mellitus-Type 2 | Phase 1 |

New Molecular Entity

New Indication or Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

# Pfizer Pipeline – August 9, 2013 (cont'd)

| Therapeutic Area | Compound Name | Mechanism of Action (Phase 3 through regulatory approval) | Indication | Phase |
|---|---|---|---|---|
| Inflammation and Immunology | Xeljanz (tofacitinib) | JAK Inhibitor | Psoriasis (Oral) | Phase 3 |
| | Xeljanz (tofacitinib) | JAK Inhibitor | Ulcerative Colitis | Phase 3 |
| | ►Xeljanz (tofacitinib) | JAK Inhibitor | Psoriatic Arthritis | Phase 3 |
| | PF-04171327 | | Rheumatoid Arthritis | Phase 2 |
| | PF-05285401 | | Ulcerative Colitis (Biologic) | Phase 2 |
| | anrukinzumab (IMA-638) | | Ulcerative Colitis (Biologic) | Phase 2 |
| | PF-00547659 | | Crohn's Disease, Ulcerative Colitis (Biologic) | Phase 2 |
| | PF-04236921 | | Crohn's Disease, Lupus (Biologic) | Phase 2 |
| | PH-797804 | | Chronic Obstructive Pulmonary Disease | Phase 2 |
| | PD-0360324 | | Sarcoidosis, *Lupus (Biologic) | Phase 2 |
| | PF-06473871 (EXC 001) | | Dermal Scarring | Phase 2 |
| | Xeljanz (tofacitinib) | | Ankylosing Spondylitis, Psoriasis (Topical), Crohn's Disease | Phase 2 |
| | Dekavil | | Rheumatoid Arthritis (Biologic) | Phase 1 |
| | PF-03715455 | | Chronic Obstructive Pulmonary Disease | Phase 1 |
| | PF-06342674 | | Diabetes Mellitus-Type 1 (Biologic) | Phase 1 |
| | ►PF-04965842 | | Lupus | Phase 1 |

* Note: Additional indications in Phase 1

New Molecular Entity

New Indication or Enhancement

► Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

# Pfizer Pipeline – August 9, 2013 (cont'd)

| Therapeutic Area | Compound Name | Mechanism of Action (Phase 3 through regulatory approval) | Indication | Phase |
|---|---|---|---|---|
| Neuroscience & Pain | Celebrex | COX-2 | Chronic Pain (U.S.) | Registration |
| | Remoxy | Mu-type opioid receptor (MOR-1) Agonist | Moderate to Severe Pain (U.S.) | Registration |
| | ALO-02 Oxycodone-naltrexone core | Mu-type opioid receptor (MOR-1) Agonist | Moderate to Severe Pain | Phase 3 |
| | Lyrica | Alpha-2 Delta Ligand | Peripheral Neuropathic Pain | Phase 3 |
| | Lyrica | Alpha-2 Delta Ligand | CR (once a day dosing) | Phase 3 |
| | tanezumab | Nerve Growth Factor Inhibitor | OA Signs and Symptoms | Phase 3 |
| | PF-05212377 (SAM-760) | | Alzheimer's Disease | Phase 2 |
| | PF-03049423 | | Stroke Recovery | Phase 2 |
| | ▶PF-04360365 (ponezumab) | | Cerebral Amyloid Angiopathy (Biologic) | Phase 2 |
| | tanezumab | | Cancer Pain (Biologic) | Phase 2 |
| | PF-05089771 | | Chronic Pain | Phase 1 |
| | PF-05236812 (AAB-003) | | Alzheimer's Disease (Biologic) | Phase 1 |
| | PF-04958242 | | Schizophrenia | Phase 1 |
| | PF-06305591 | | Chronic Pain | Phase 1 |
| | PF-06273340 | | Acute and Chronic Pain | Phase 1 |

New Molecular Entity

New Indication or Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

# Pfizer Pipeline – August 9, 2013 (cont'd)

| Therapeutic Area | Compound Name | Mechanism of Action (Phase 3 through regulatory approval) | Indication | Phase |
|---|---|---|---|---|
| Oncology | dacomitinib (PF-00299804) | pan-HER Inhibitor | Previously Treated Advanced Non-Small Cell Lung Cancer | Phase 3 |
| | dacomitinib (PF-00299804) | pan-HER Inhibitor | 1st Line Non-Small Cell Lung Cancer | Phase 3 |
| | Xalkori (crizotinib) | c-MET-ALK Inhibitor | ALK-Positive 1st and 2nd Line (supports potential full approval in the U.S.) Non-Small Cell Lung Cancer, *Cancer | Phase 3 |
| | Inlyta (axitinib) | VEGF Tyrosine Kinase Inhibitor | Renal Cell Carcinoma Adjuvant (Asia only) | Phase 3 |
| | Sutent | Multiple Tyrosine Kinase Inhibitor | Renal Cell Carcinoma Adjuvant | Phase 3 |
| | palbociclib (PD-0332991) | CDK 4,6 Kinase Inhibitor | 1st Line Advanced Breast Cancer, *Cancer | Phase 3 |
| | inotuzumab ozogamicin | CD22-targeted cytotoxic agent | Acute Lymphoblastic Leukemia (Biologic) | Phase 3 |
| | Inlyta (axitinib) | | Liver Cancer | Phase 2 |
| | dacomitinib (PF-00299804) | | Cancer | Phase 2 |
| | PF-05212384 | | Endometrial Cancer, *Cancer | Phase 2 |
| | PF-03084014 | | Cancer | Phase 1 |
| | PF-03446962 | | 2nd Line Hepatocellular Carcinoma (Biologic) | Phase 1 |
| | PD-0325901 | | Cancer (in combination with PF-05212384) | Phase 1 |
| | PF-05082566 | | Cancer (Biologic) | Phase 1 |
| | PF-04449913 | | Acute Myelocytic Leukemia | Phase 1 |

New Molecular Entity

New Indication or Enhancement

* Note: Additional indications in Phase 1

# Pfizer Pipeline – August 9, 2013 (cont'd)

| Therapeutic Area | Compound Name | Mechanism of Action (Phase 3 through regulatory approval) | Indication | Phase |
|---|---|---|---|---|
| **Vaccines** | MnB rLP2086 (PF-05212366) | | Adolescent and Young Adult Meningitis B | Phase 3 |
| | 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) (PF-06290510) | | Staph Aureus | Phase 2 |
| | PF-05402536 | | Smoking Cessation | Phase 1 |
| | PF-06425090 | | Clostridium Difficile Colitis | Phase 1 |
| | PF-06444752 | | Asthma | Phase 1 |

New Molecular Entity

# Pfizer Pipeline – August 9, 2013 (cont'd)

| Therapeutic Area | Compound Name | Mechanism of Action (Phase 3 through regulatory approval) | Indication | Phase |
|---|---|---|---|---|
| Other Areas of Focus (Rare Diseases) | tafamidis meglumine | Transthyretin (TTR) Dissociation Inhibitor | Transthyretin familial amyloid polyneuropathy (U.S.) | Registration |
| | rivipansel (GMI-1070) | | Vaso-occlusive crisis associated with Sickle Cell Disease | Phase 2 |
| | PF-05280602 | | Hemophilia (Biologic) | Phase 1 |
| | PF-06252616 | | Muscular Dystrophies (Biologic) | Phase 1 |
| | PF-06687859 | | Spinal Muscular Atrophy | Phase 1 |
| Other Areas of Focus (Biosimilars) | PF-05280586 | | Rheumatoid Arthritis (Biosimilar) | Phase 1 |
| | PF-05280014 | | Metastatic Breast Cancer (Biosimilar) | Phase 1 |
| | ▶PF-06410293 | | Rheumatoid Arthritis (Biosimilar) | Phase 1 |
| | ▶PF-06438179 | | Rheumatoid Arthritis (Biosimilar) | Phase 1 |
| Other Areas of Focus | bazedoxifene-conjugated estrogens | Tissue Selective Estrogen Complex | Menopausal Vasomotor Symptoms (U.S.) / (EU) | Registration |
| | Viviant | Selective Estrogen Receptor Modulator | Osteoporosis Treatment and Prevention (U.S.) | Registration |
| | Zithromax/chloroquine | 5-OS Ribosome Inhibitor | Malaria | Phase 3 |
| | bosutinib | | Autosomal Dominant Polycystic Kidney Disease | Phase 2 |

New Molecular Entity | New Indication or Enhancement | Biosimilar

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

# Projects Discontinued from Development since May 9, 2013

| Compound Name | Mechanism of Action (Phase 3 through regulatory approval) | Indication | Phase |
|---|---|---|---|
| tofacitinib | JAK Inhibitor | Rheumatoid Arthritis (EU)[1] | Registration |
| inotuzumab ozogamicin | | Aggressive Non-Hodgkin Lymphoma (Biologic) | Phase 3 |
| ACC-001 (PF-05236806) | | Alzheimer's Disease[2] | Phase 2 |
| PNU-100480 | | Tuberculosis | Phase 2 |

1. We plan to work with the EMA to determine what additional data will be needed in order to resubmit a Marketing Authorization Application (MAA), and anticipate this will result in a several year delay.

2. Two ACC-001 PET imaging trials that are ongoing in the US will continue as planned since these clinical trials are collecting additional biomarker data in mild to moderate AD and in subjects with early Alzheimer's disease.

New Molecular Entity